Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

466 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Martin DS, Stolfi RL, Sawyer RC. Martin DS, et al. Cancer Chemother Pharmacol. 1989;24(1):9-14. doi: 10.1007/BF00254098. Cancer Chemother Pharmacol. 1989. PMID: 2720896
Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.
Malik ST, Martin D, Hart I, Balkwill F. Malik ST, et al. Among authors: martin d. Br J Cancer. 1991 Mar;63(3):399-403. doi: 10.1038/bjc.1991.92. Br J Cancer. 1991. PMID: 2003980 Free PMC article.
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R. Seiter K, et al. Among authors: martin d. Cancer. 1993 Mar 1;71(5):1875-81. doi: 10.1002/1097-0142(19930301)71:5<1875::aid-cncr2820710526>3.0.co;2-9. Cancer. 1993. PMID: 8448752
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Kelsen DP, Martin D, O'Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J. Kelsen DP, et al. Among authors: martin d. J Clin Oncol. 1997 Apr;15(4):1511-7. doi: 10.1200/JCO.1997.15.4.1511. J Clin Oncol. 1997. PMID: 9193347 Clinical Trial.
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W. Kemeny N, et al. Among authors: martin d. J Clin Oncol. 1992 May;10(5):747-52. doi: 10.1200/JCO.1992.10.5.747. J Clin Oncol. 1992. PMID: 1569447
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA).
Kemeny N, Seiter K, Martin D, Urmacher C, Niedzwiecki D, Kurtz RC, Costa P, Murray M. Kemeny N, et al. Among authors: martin d. Ann Intern Med. 1991 Dec 15;115(12):946-51. doi: 10.7326/0003-4819-115-12-946. Ann Intern Med. 1991. PMID: 1824554 Clinical Trial.
A concomitant ATP-depleting strategy markedly enhances anticancer agent activity.
Martin DS, Spriggs D, Koutcher JA. Martin DS, et al. Apoptosis. 2001 Feb-Apr;6(1-2):125-31. doi: 10.1023/a:1009692631748. Apoptosis. 2001. PMID: 11321035 Review.
ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach.
Martin DS, Bertino JR, Koutcher JA. Martin DS, et al. Cancer Res. 2000 Dec 15;60(24):6776-83. Cancer Res. 2000. PMID: 11156364 Review. No abstract available.
Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis.
Martin DS, Stolfi RL, Colofiore JR. Martin DS, et al. Cancer Invest. 1997;15(4):372-81. doi: 10.3109/07357909709039742. Cancer Invest. 1997. PMID: 9246161 Review. No abstract available.
Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade.
Martin DS, Schwartz GK. Martin DS, et al. Oncol Res. 1997;9(1):1-5. Oncol Res. 1997. PMID: 9112254
466 results
Jump to page
Feedback